Interpreting a Negative Trial in Complex Perianal Crohn’s Disease

The current publication of the phase 3 ADMIRE CD II trial marks a pivotal moment in the development of stem cell therapy for complex perianal Crohn’s disease.1 Darvadstrocel (Alofisel), once regarded as a long-awaited breakthrough for one of the most challenging manifestations of Crohn’s disease,2 failed to demonstrate superiority over placebo, leading to its withdrawal from the European market in December 2024, >1 year before the official publication.3 Although the negative primary outcome of ADMIRE CD II is unequivocal, its interpretation and broader implications warrant careful consideration.